A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

Ritesh R. Kotecha,Sahil D. Doshi,Andrea Knezevic,Joshua Chaim,Yingbei Chen, Rachel Jacobi,Mark Zucker,Ed Reznik,Deaglan McHugh,Neil J. Shah,Emily Feld,David H. Aggen, William Rafelson,Han Xiao,Maria I. Carlo,Darren R. Feldman,Chung-Han Lee,Robert J. Motzer,Martin H. Voss

European urology oncology（2023）

引用 0|浏览28

暂无评分

摘要

In a phase 2 trial evaluating poly ADP-ribose polymerase inhibitors and programmed death-ligand 1 inhibition in two treatment-refractory, genomically defined, advanced kidney cancer cohorts—(1) Von Hippel-Lindau–altered renal cell carcinoma (RCC) and (2) fumarate hydratase- or succinate dehydrogenase-deficient RCC and renal medullary carcinoma, no objective responses were seen.

查看译文

关键词

Fumarate hydratase deficient,Immunotherapy,Poly ADP-ribose polymerase inhibitor,Renal cell carcinoma,Renal medullary cancer,Metastatic,Programmed death-ligand 1,Succinate dehydrogenase deficient,SMARCB1,Von Hippel-Lindau altered

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要